| 0.2763 0.012 (4.66%) | 07-15 12:46 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.36 | 1-year : | 0.42 |
| Resists | First : | 0.31 | Second : | 0.36 |
| Pivot price | 0.26  |
|||
| Supports | First : | 0.23 | Second : | 0.19 |
| MAs | MA(5) : | 0.26 |
MA(20) : | 0.28 |
| MA(100) : | 0.38 |
MA(250) : | 0.89 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31 |
D(3) : | 21.5 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 2.09 | Low : | 0.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ARAY ] has closed below upper band by 32.2%. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.29 - 0.29 | 0.29 - 0.29 |
| Low: | 0.25 - 0.26 | 0.26 - 0.26 |
| Close: | 0.26 - 0.26 | 0.26 - 0.27 |
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
Tue, 07 Jul 2026
Neuberger Berman holds 5.1% of Accuray (NASDAQ: ARAY) — 6.07M shares - Stock Titan
Fri, 26 Jun 2026
Accuray (ARAY) Stock Sees Fair Value Cut After Downgrades And Lower Growth Assumptions - Yahoo Finance
Thu, 25 Jun 2026
ARAY Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 29 May 2026
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules - PR Newswire
Wed, 13 May 2026
Need To Know: Analysts Just Made A Substantial Cut To Their Accuray Incorporated (NASDAQ:ARAY) Estimates - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 119 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 69.3 (%) |
| Shares Short | 4,830 (K) |
| Shares Short P.Month | 8,090 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | -10.8 % |
| Operating Margin | -2.5 % |
| Return on Assets (ttm) | -1.7 % |
| Return on Equity (ttm) | -101.1 % |
| Qtrly Rev. Growth | -7.5 % |
| Gross Profit (p.s.) | 0.96 |
| Sales Per Share | 3.6 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 29.4 |
| Price to Book value | 0.81 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -1.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|